BioCentury
ARTICLE | Financial News

MedDay raises EUR 34M in series B

April 9, 2016 1:23 AM UTC

MedDay S.A.S. (Paris, France) raised EUR 34 million ($38.7 million) in a series B round led by new investor Edmond de Rothschild Investment Partners. Sofinnova Partners and the InnoBio and Large Venture funds of Bpifrance also participated.

CEO Frederic Sedal told BioCentury the company hopes to have data by YE18 from a Phase III study of lead candidate MD1003 to treat progressive multiple sclerosis, and hopes to submit the data to FDA as early as 2019. In April 2015, the candidate met the primary endpoint of another Phase III study in the indication (see BioCentury Extra, April 17, 2015). ...